The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

altanpharma.eu

Stage

Acquired | Acquired

Revenue

$0000 

About Altan Pharma

Altan Pharma is a specialized pharmaceutical company that develops, manufactures, and markets injectable drugs for the hospital sector and other suppliers.On June 18, 2021, Altan Pharma was acquired by Ethypharm. The terms of the transaction were not disclosed.

Altan Pharma Headquarter Location

Calle Cólquide 6, portal 2 1ª planta, oficina D, Edificio Prisma

Madrid, 28231,

Spain

+34 91 710 36 30

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Altan Pharma Patents

Altan Pharma has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/21/2016

4/17/2018

Analgesics, Coordination compounds, Equilibrium chemistry, Physiology, Respiratory physiology

Grant

Application Date

3/21/2016

Grant Date

4/17/2018

Title

Related Topics

Analgesics, Coordination compounds, Equilibrium chemistry, Physiology, Respiratory physiology

Status

Grant

Latest Altan Pharma News

  • Where is Altan Pharma's headquarters?

    Altan Pharma's headquarters is located at Calle Cólquide 6, portal 2, Madrid.

  • What is Altan Pharma's latest funding round?

    Altan Pharma's latest funding round is Acquired.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.